Twist Bioscience Corp — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 3/100
What the filing says
CEO Emily M. Leproust and CFO Adam Laponis certified the Q2 2026 10-Q (quarter ended June 30, 2026) filed August 3, 2026. Both officers attested that financial statements fairly present the company's condition and operations, disclosure controls are effective, and no material weaknesses or fraud were identified. The filing contains only standard Sarbanes-Oxley certification exhibits with no substantive operational, financial, or control disclosures.
Why this rating
Routine SOX certification exhibits only; no financial data, transactions, or business developments disclosed. Boilerplate compliance filing.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.